Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 23235570)

1.

Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus.

Wong MG, Perkovic V, Woodward M, Chalmers J, Li Q, Hillis GS, Yaghobian Azari D, Jun M, Poulter N, Hamet P, Williams B, Neal B, Mancia G, Cooper M, Pollock CA.

Kidney Int. 2013 Feb;83(2):278-84. doi: 10.1038/ki.2012.383. Epub 2012 Dec 12.

PMID:
23235570
2.

Prediction of renal end points in chronic kidney disease.

Al-Aly Z.

Kidney Int. 2013 Feb;83(2):189-91. doi: 10.1038/ki.2012.418.

PMID:
23364584
3.

Activation of transforming growth factor-beta1 in diabetic kidney disease.

Hellmich B, Schellner M, Schatz H, Pfeiffer A.

Metabolism. 2000 Mar;49(3):353-9.

PMID:
10726914
4.

The changes of serum sKlotho and NGAL levels and their correlation in type 2 diabetes mellitus patients with different stages of urinary albumin.

Wu C, Wang Q, Lv C, Qin N, Lei S, Yuan Q, Wang G.

Diabetes Res Clin Pract. 2014 Nov;106(2):343-50. doi: 10.1016/j.diabres.2014.08.026. Epub 2014 Sep 16.

PMID:
25263500
5.

Comparison of serum cystatin C, serum creatinine, measured GFR, and estimated GFR to assess the risk of kidney failure in American Indians with diabetic nephropathy.

Pavkov ME, Knowler WC, Hanson RL, Williams DE, Lemley KV, Myers BD, Nelson RG.

Am J Kidney Dis. 2013 Jul;62(1):33-41. doi: 10.1053/j.ajkd.2012.11.044. Epub 2013 Jan 21.

6.
7.

Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy.

Shaker OG, Sadik NA.

Hum Exp Toxicol. 2013 Oct;32(10):1089-96. doi: 10.1177/0960327112470274. Epub 2013 Mar 20.

PMID:
23515495
8.
9.

Reducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathy.

Kim SM, Choi YW, Seok HY, Jeong KH, Lee SH, Lee TW, Ihm CG, Lim SJ, Moon JY.

Nephron Exp Nephrol. 2012;121(3-4):e109-21. doi: 10.1159/000343567. Epub 2013 Jan 9.

PMID:
23307286
10.

[Urine TGF-beta1 concentration in patients with type II diabetes mellitus--prognostic values].

Paczek L, Kropiewnicka HE, Senatorski G, Bartłomiejczyk I.

Pol Arch Med Wewn. 2002 Aug;108(2):745-52. Polish.

PMID:
12476894
11.

Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.

Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R.

Diabetes Care. 2013 Nov;36(11):3639-45. doi: 10.2337/dc13-0683. Epub 2013 Jul 17.

12.
13.

The influence of sex on renal function decline in people with Type 2 diabetes.

de Hauteclocque A, Ragot S, Slaoui Y, Gand E, Miot A, Sosner P, Halimi JM, Zaoui P, Rigalleau V, Roussel R, Saulnier PJ, Hadjadj Samy S; SURDIAGENE Study group.

Diabet Med. 2014 Sep;31(9):1121-8. doi: 10.1111/dme.12478. Epub 2014 May 21.

PMID:
24773061
14.

Measurement of urinary TGF-β1 in patients with diabetes mellitus and normal controls.

Tsapenko MV, Nwoko RE, Borland TM, Voskoboev NV, Pflueger A, Rule AD, Lieske JC.

Clin Biochem. 2013 Oct;46(15):1430-5. doi: 10.1016/j.clinbiochem.2013.05.041. Epub 2013 May 16.

PMID:
23685222
15.

Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans.

Suthanthiran M, Gerber LM, Schwartz JE, Sharma VK, Medeiros M, Marion R, Pickering TG, August P.

Kidney Int. 2009 Jul;76(1):72-80. doi: 10.1038/ki.2009.66. Epub 2009 Mar 11.

17.

[Cytokines in noninvasive diagnostics of diabetic nephropathy progression].

Senatorski G, Paczek L, Kropiewnicka E, Bartłomiejczyk I.

Pol Merkur Lekarski. 2002 Nov;13 Suppl 1:28-32. Polish.

PMID:
12621778
18.

Urinary transforming growth factor-beta 1 in various types of nephropathy.

De Muro P, Faedda R, Fresu P, Masala A, Cigni A, Concas G, Mela MG, Satta A, Carcassi A, Sanna GM, Cherchi GM.

Pharmacol Res. 2004 Mar;49(3):293-8.

PMID:
14726227
19.

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.

Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR.

Arch Intern Med. 2012 May 28;172(10):761-9. doi: 10.1001/archinternmed.2011.2230. Review. Erratum in: Arch Intern Med. 2012 Jul 23;172(14):1095.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk